From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Lenacapavir's biannual administration may reduce stigma and improve adherence to HIV prevention strategies. New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure prophylaxis (PrEP), which reduces the risk of contracting HIV through sex ...

Physicians and their patients report that engagement in an HIV-based community rivals drug effectiveness in the ongoing efforts to curtail an epidemic. Confronting the HIV Epidemic: There's an App ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Extreme weather events are associated with disruptions to HIV services. Owing to the design of the included studies, we could ...

The counties identified as priority jurisdictions by the Centers for Disease Control and Prevention ... new HIV infections by 90% by 2030. To end the HIV epidemic in Latinx communities, cities must ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

This dynamic gathering provided a platform for experts to share cutting-edge evidence and discuss the latest tools and strategies in HIV prevention science. The week-long event included 16 invited ...